RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks. Dungrawala H, Bhat KP, Le Meur R, Chazin WJ, Ding X, Sharan SK, Wessel SR, Sathe AA, Zhao R, Cortez D (2017) Mol Cell 67: 374-386.e5 Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Nat Rev Clin Oncol 13: 674-690 MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB (2011) Cancer Res 71: 2632-42 Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition. Yang ES, Nowsheen S, Rahman MA, Cook RS, Xia F (2012) Cancer Res 72: 5547-55 Prospects and challenges for the development of new therapies for Ewing sarcoma. Grohar PJ, Helman LJ (2013) Pharmacol Ther 137: 216-24 Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Amiri KI, Ha HC, Smulson ME, Richmond A (2006) Oncogene 25: 7714-22 Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN (2014) Oncotarget 5: 5637-50 A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. Nirodi C, NagDas S, Gygi SP, Olson G, Aebersold R, Richmond A (2001) J Biol Chem 276: 9366-74 Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. Wiltshire TD, Lovejoy CA, Wang T, Xia F, O'Connor MJ, Cortez D (2010) J Biol Chem 285: 14565-71 Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS (2016) Oncologist 21: 172-7 The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D (2018) Gynecol Oncol 149: 575-584
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.